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Abstract
The oncogene Bmi-1 is a member of the Polycomb group gene family. Its expression is found to be greatly increased
in a number of malignant tumors including breast cancer. This could suggest Bmi-1 as a potent therapeutic target. In
this study, RNAi was introduced to down-regulate the expression of Bmi-1 in a highly malignant breast adeno-
carcinoma cell line, MCF-7. A thorough study of the biological behavior and chemosensitivity changes of the MCF-7
cellswascarriedoutincontexttothetherapeuticpotentialofBmi-1.TheresultsobtainedindicatedthatsiRNAtarget-
ing of Bmi-1 could lead to an efficient and specific inhibition of endogenous Bmi-1 activity. The mRNA and protein ex-
pression of Bmi-1 were determined by RT-PCR and Western blot, respectively. Furthermore, silencing of Bmi-1
resultedinadrasticinhibitionofthegrowthofMCF-7cellsaswellasG1/Sphasetransition.Thenumberoftargetcells
was found to increase in phase G0/G1 and decrease in the S phase, but no increase in the basal level of apoptosis
was noticed. On the other hand, a reduction in the expression of cyclin D1 and an increase in the expression of p21
were also noticed. Silencing of Bmi-1 made the MCF-7 cells more sensitive to the chemotherapeutic agent
doxorubicin and induced a significantly higher percentage of apoptotic cells. Here, we report on a study regarding the
RNAi-mediated silencing of the Bmi-1 gene in breast cancer.
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Introduction
Breast cancer is one of the most common malignan-
cies affecting women worldwide. Despite the recent devel-
opment of various therapeutic strategies, the prognosis for
thiscancerstillremainspoor.Thus,moreeffortsareneeded
to understand its molecular pathway in order to develop an
effective therapy to achieve cure.
Bmi-1 (B-cell-specific moloney murine leukemia vi-
rus insertion site 1) was originally identified as an onco-
genicpartnerofc-Mycinmurinelymphomagenesis(Haupt
et al., 1993; Van Lohuizen et al., 1991). It is a component
of the Polycomb repressive complex 1, which represses
gene expression through chromatin modifications (Valk-
Lingbeek et al., 2004). Previous studies have revealed that
Bmi-1 is involved in the regulation of stem-cell-associated
genestocontrolcellself-renewinganddifferentiation(Park
etal.,2003;Molofskyetal.,2005).Otherstudiesalsodem-
onstrated that Bmi-1 regulates the differentiation and
clonogenic self-renewal of I-type neuroblastoma cells (Cui
et al., 2006).
Bmi-1 is overexpressed in several malignancies, such
as non-small cell lung cancer (Vonlanthen et al., 2001),
colorectal cancer (Kim et al., 2004a), nasopharyngeal car-
cinoma (Song et al., 2006) and oral cancer (Kang et al.,
2007). On the other hand, loss of Bmi-1 with RNA interfer-
ence (RNAi) was effective in suppressing growth and
tumorigenicity of cancer cells (such as SH-SY5Y neuro-
blastoma and ovary adenocarcinoma) (Liu et al., 2006a).
This is consistent with the study of Cui et al. (2007) that
showed that down-regulation of Bmi-1 impaired the ability
of neuroblastoma cells to grow in soft agar and tumo-
rigenicityinimmunodeficientmice.Therefore,silencingof
Bmi-1 may be of great importance in the design and devel-
opment of anticancer therapy. However, to our best knowl-
edge, there is so far no study in the literature on the
therapeutic potential of Bmi-1 in breast cancer cell lines.
Notably, Bmi-1 was found to regulate self-renewal of
breastcancerstemcellsandtoaltermammarydevelopment
in a humanized nonobese diabetic-severe combined
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Research Articleimmunodeficient (SCID) mouse model (Liu et al., 2005;
2006b).OverexpressionofBmi-1inducestelomeraseactiv-
ity and immortalizes human mammary epithelial cells
(MECs), suggesting a potential role for Bmi-1 in the devel-
opmentofhumanbreastcancer(Dimrietal.,2002).Ampli-
fication of the Bmi-1 gene is detected in approximately
85% of human invasive ductal breast cancers and this
genomic alteration is correlated with axillary lymph node
metastasesandpositiveestrogenreceptorstatus(Kimetal.,
2004b). Furthermore, the Bmi-1 mRNA transcript levels
are higher in plasma from breast carcinoma patients than in
healthy controls, and this amplification of Bmi-1 is predic-
tive of poor clinical outcome (Silva et al., 2007).
Doxorubicin has emerged as one of the most widely
used chemotherapeutic agents for breast cancer. Although
there is initial response to this chemotherapeutic agent, re-
sistance is seen to develop over a period of time. This leads
to a phenotypically more aggressive cell variant with an in-
clination to metastasize. So, increasing chemosensitivity is
very important for breast cancer therapy.
A study on Bmi-1 mRNA levels in several breast can-
cer cell lines (MCF-7, MDA-MB-468, MDA-MB-231,
T47D) was carried out. In MCF-7 and MDA-MB-231
Bmi-1 expression was found to be maximal. In order to in-
vestigatethepossibilityofturningBmi-1intoanovelthera-
peutic agent for the treatment of breast cancer, MCF-7 was
chosen to silence the expression of Bmi-1 with the highly
specific post-transcriptional suppression of RNAi. There-
after, proliferation, cell cycle status, apoptosis, and chemo-
sensitivity to doxorubicin were also studied. The results
obtained suggest that targeting of Bmi-1 may be used as a
potential and specific therapeutic tool for the treatment of
breast cancer.
Materials and Methods
Cell line and reagents
The highly malignant human breast adenocarcinoma
cell line MCF-7 was obtained from Dr. Yin (Third Military
Medical University, China). The human Bmi-1 gene short
hairpin RNA (shRNA)-expressing plasmid pSuper-
retro/Bmi-1 si and a control plasmid pSuper-retro/GFP si
expressing Green Fluorescent Protein (GFP) shRNA (Cui
et al., 2007) were used. The Bmi-1 siRNA sequence was
5’-AATGGACATACCTAATACT-3’, position 546 to
564 bp relative to the start codon. The GFP target sequence
was 5’-GCAAGCTGACCCTGAAGTTC-3’. Lipofecta-
mine 2000 Reagent was purchased from Invitrogen (USA),
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and doxorubicin hydrochloride were pur-
chased from Sigma (USA).
Cell culture and gene-silencing assays
The MCF-7 cell line was maintained as a monolayer
culture in RPMI-1640 medium (Hyclone, USA) with
L-glutamine (2 mM) and 10% fetal calf serum (Hyclone,
USA) in a humidified atmosphere supplemented with 5%
CO2 at 37 °C. When the density of cells reached 90%-95%,
transfections were carried out with Lipofectamine 2000 re-
agent, using 2 mg of expression vector/mL serum-free me-
dium, as recommended by the manufacturer. The cells
which were transfected with pSuper-retro/Bmi-1 si were
named Bmi-1si, and the cells transfected with pSuper-
retro/GFP si were named GFPsi. The MCF-7 cells devoid
of transfection were used as blank control. After6ho f
transfection, the medium was replaced by serum-contai-
ning medium.
RNA preparation and semiquantitative RT-PCR
After 48 h of transfection, the total RNA of the cells
was extracted using the Trizol method (Invitrogen, USA)
according to the manufacturer’s directions, and quantified
by spectrophotometry at 260 nm. cDNA was generated
from 3-5 g of total RNA, using SuperScript II reverse
transcriptase and random primers, according to the manu-
facturer’s protocol (Invitrogen, USA). PCR-based amplifi-
cation with rTaq DNA polymerase (Takara, Japan) was
performed under standard conditions. GAPDH was used as
internal control of integrity and uniformity of the sample
preparation. The PCR conditions maintained were as fol-
lows: pre-denaturing at 94 °C for 5 min, followed by 30 re-
actioncyclesat94°Cfor30s,51°Cfor30s,72°Cfor30s,
and a final extension cycle at 72 °C for 5 min. The PCR
products were analyzed on a 1.5% agarose gel stained with
ethidium bromide, and the resultant target bands were
densitometricallyanalyzedbyusingVistraFluorImagerSI
(Molecular Dynamics Inc., USA). The ratio of target gene
to GAPDH OD value was used to represent the relative in-
tensity of the target product. Primers were designed with
Primer Premier 5.0 software, according to the human se-
quences obtained from Medline. The primers were de-
signed as follows: Bmi-1, 5’-GACCACTACTGAATATA
AGG-3’ (sense), and 5’-CATTTGTCAGTCCATCTCTC-
-3’(anti-sense);GAPDH,5’-CATGAGAAGTATGACAA
CAGCCT-3’ (sense), and 5’-CGTCCTTCCACGATA
CCAAAGT-3’ (anti-sense).
Immunofluorescent staining
Cells were grown on glass coverslips and transfected
with retrovirus vectors. 48 h after transfection, the culture
medium was aspirated and the cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for
15 min and permeabilized in 0.2% Triton X-100 in PBS for
5 min at room temperature. Cells were blocked with 3%
BSAinPBSfor1hatroomtemperatureandthenincubated
withBmi-1antibody(1:100dilution,Upstate,USA)at4°C
overnight. Then, the cells were washed in PBS (310 min)
andincubatedwithasecondaryRhodamine-conjugatedan-
tibody (1:100 dilution, Zhongshan, China) at 37 °C for 1 h.
ThecellswerewashedinPBS(410min),followedbyaddi-
698 Wu et al.tion of the mixture of ProLong mounting medium and Pro-
Long Antifade reagent onto the slides. Fluorescent images
were taken by confocal laser-scanning microscopy using a
Leica TCS SP confocal system attached to a Leica DM
IRBE microscope; 568 nm laser wavelength was used for
analysis.
Western blot analysis
Total protein was isolated and quantified. Cells trans-
fected for 48 h were harvested, washed with ice-cold PBS
and lysed in lysis buffer containing 25 mM Tris-HCl, pH
8.0,137mMNaCl,2.7mMKCl,1%TritonX-100andpro-
tease inhibitor mixture (Sigma, USA) at 4 °C for 30 min,
followed by brief sonication. All the experimental steps
were performed on ice. After centrifugation at 16,220 g at
4 °C for 10 min, supernatants were collected, and the pro-
tein concentration was measured with the BCA assay re-
agent (Bioteke, China) according to the manufacturer’s
protocol. Following sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), the proteins were
transferred onto a PVDF membrane (Immobilon, USA).
After saturation, the membranes were incubated at room
temperature for 2 h in TBS with 0.1%Tween-20 (TBS-T)
containing5%nonfatdrymilk,andsubsequentlyincubated
with primary antibodies against Bmi-1 (1:600 dilution),
cyclin D1 and p21 (1:200 dilution, Santa Cruz, USA) over-
night at 4 °C. Peroxidase conjugated IgG antibodies
(MultiSciencesBiotech,China)wereusedassecondaryan-
tibodies. The protein was detected using the ECL detection
kit (keygen, China) following the manufacturer’s protocol.
-actin immunoblotting was used as protein loading con-
trol.
MTT assay
The MTT assay was used to detect the effect of
plasmids on the growth of MCF-7 cells and to determine
the50%inhibitoryconcentration(IC50)ofdoxorubicin.For
measurement of cell growth curves, cells (110
4/well) were
platedinto96-wellplatesandallowedtogrowfor4daysaf-
ter transfection with pSuper-retro/Bmi-1 si and pSuper-
retro/GFP si. Growth curves were plotted as optical density
(570 nm) versus days after transfection. To study the IC50,
48 h after transfection, cells were treated with various con-
centrations of doxorubicin (0.03-100 g/mL) for 72 h. At
each time point, 10 L of MTT stock solution (5 mg/mL in
PBS) were added to each microtiter well and incubated for
4 h at 37 °C. After aspiration of the medium, 150 Lo f
dimethyl sulfoxide was added and mixed, and absorbances
were measured at a wavelength of 570 nm. The rate of cell
growth inhibition (IR) was calculated according to the fol-
lowingequation:IR=[1–A570(drug)/A570(control)] 100%,
where A570 (drug) is the absorbance of the cells exposed to
doxorubicinandA570(control)istheabsorbanceofthecells
without doxorubicin treatment.
Cell cycle assay
The cell cycle was analyzed by using flow cytometry
(FCM) with propidium iodide staining. Both floating and
attached cells were collected by trypsin digestion and low-
speedcentrifugation,washedwithcoldPBS,andthenfixed
inice-cold70%ethanolovernight.Thefixedcellswerecol-
lectedbybriefcentrifugationandresuspendedinPBS,after
which the cells were treated with RNaseA and stained with
propidium iodide for1ha troom temperature, and finally
analyzed by FCM.
Apoptosis assay
Apoptosis was assayed using the Annexin V-FITC
Apoptosis Kit (keygen, China) according to the manufac-
turer’s instructions. Briefly, the cells were harvested and
washed twice with PBS, followed by resuspension in
Annexin-V binding buffer, and then FITC-conjugated
Annexin V and PI were added. After incubation for 10 min
atroomtemperatureinthedark,anotherbindingbufferwas
added, and the samples were immediately analyzed using
FCM.
Statistical analysis
All experiments were performed at least three times
and statistical analysis was done using the SPSS13.0 pack-
age(SPSSInc.,Chicago,USA).Thevalueswereexpressed
as mean  SD. The ANOVA test was used whenever more
than two groups were compared, and the significance level
was set at p < 0.05. Dunnett’s post hoc test was used to ana-
lyze multiple comparisons. P values of less than 0.05
(p < 0.05) were considered to be statistically significant.
Results
Inhibition of Bmi-1 expression at the mRNA and
protein levels
In the first phase of our study, we determined the si-
lencing of the Bmi-1 gene activity in the targeted MCF-7
cells. MCF-7 cells were transiently transfected with
pSuper-retro/Bmi-1 si and pSuper-retro/GFP si. After
transfection for 48 h, total RNA and whole-cell lysates
were prepared and subjected to semiquantitative RT-PCR
and Western blot, respectively. Figure 1 clearly indicates
that the Bmi-1/GAPDH ratio of band density in Bmi-1si
was significantly lower and also shows a 67% reduction in
density compared to the blank control. In GFPsi, the same
ratio showed a 5.2% reduction compared to the blank con-
trol. The differences between Bmi-1si and controls were
statistically significant (p < 0.05). Similarly, the protein
levelofBmi-1inBmi-1sishowedareductionofupto70%,
clearly indicating a marked difference from that of the
blank control and GFPsi (p < 0.05) (Figure 2B). Compared
with the blank control and GFPsi, immunofluorescent
staining showed a significantly weaker fluorescence in the
Bmi-1si MCF-7 cells (Figure 2A).
Bmi-1 silencing affects growth and apoptosis of MCF-7 699Bmi-1 silencing inhibited MCF-7 cell proliferation
The MTT assay indicated strong inhibition in the
growthrateofBmi-1siMCF-7cellscomparedtothatofthe
blank control and GFPsi. After 24 h and 48 h of trans-
fection, the optical density (570 nm) in Bmi-1si showed no
significant differences compared to the blank control and
GFPsi. However, 72 h after transfection, there were
significant differences between Bmi-1si and controls (Fig-
ure 3).
Bmi-1 silencing induced G0/G1 cell cycle arrest and
abnormal expression of cyclin D1 and p21
The effect of Bmi-1 silencing on cell cycle progres-
sion was analyzed using FCM. Bmi-1 silencing induced an
obvious increase in the number of cells at G0/G1 phase and
reduction in S phase, as 77.10% of the MCF-7 cells in
Bmi-1si were noticed at G0/G1 phase, compared to 63.75%
and 64.84% cells in the blank control and GFPsi, respec-
tively (Figure 4A). There were significant differences be-
tween Bmi-1si and controls (p < 0.05). Western blot results
clearly showed a reduction in the expression of cyclin D1
and an increase of p21 in Bmi-1si compared to the blank
control and GFPsi (Figure 4B, C).
Apoptosis not induced by Bmi-1 silencing
The apoptotic rate was examined in three groups 48 h
after transfection and the results are shown in Figure 5A.
The basal level of apoptosis in Bmi-1si was 4.94%, com-
pared to 3.18% and 2.84% in the blank control and GFPsi,
respectively. No significant differences in cell apoptosis
were noticed among these three groups.
Bmi-1 silencing increased doxorubicin-induced
apoptosis
The apoptotic rate was further examined in cells after
treatment with 1 g/mL doxorubicin for 48 h. The FCM
data showed that the apoptotic rate in Bmi-1si treated with
doxorubicin was 37%, as compared to 21% in the blank
controlalsowithdoxorubicin.Thelevelsofapoptosisinthe
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Figure 1 - RT-PCR analysis of Bmi-1 mRNA level of MCF-7 cells 48 h
after transfection. The ratio of band density for Bmi-1 to GAPDH in
Bmi-1si was significantly lower, showing a 67% reduction in density as
compared to the blank control; in GFPsi, the ratio showed a 5.2% reduc-
tion compared to the blank control. There were significant differences be-
tween Bmi-1si and controls (p < 0.05). Bar graphs represent the results of
the densitometry analysis of Bmi-1, expressed as a percentage of the ratio
(molecule of interest/GAPDH mRNA) detected in the control (*p < 0.05
vs. control).
Figure 2 - Effect of Bmi-1 silencing on the expression of Bmi-1 protein in
MCF-7 cells. (A) immunofluorescent staining of Bmi-1 48 h after trans-
fection, showing a significantly weaker fluorescence in MCF-7 cells of
Bmi-1si compared to the blank control and GFPsi (Scale bars, 100 m).
(B) Western blot analysis of Bmi-1 expression 48 h after transfection,
showing a reduction of up to 70% in the protein level of Bmi-1, clearly in-
dicating a marked difference from that of the blank control and GFPsi
(p < 0.05).
Figure 3 - Effect of Bmi-1 silencing on proliferation of MCF-7 cells.
Growth curves of MCF-7 cells were analyzed by MTT assay. At 24 h and
48 h after transfection, the optical density (570 nm) in Bmi-1si showed no
significant differences compared to the blank control and GFPsi. How-
ever, 72 h after transfection, there were significant differences between
Bmi-1si and controls. The MTT assay indicated strong inhibition in the
growth rate of MCF-7 cells in Bmi-1si. Each value represents the mean
standard deviation (SD) of triplicate cultures.blank control and Bmi-1si were 6.70% and 6.72%, respec-
tively (Figure 5B). The differences between Bmi-1si
treated with doxorubicin and the blank control treated with
doxorubicin were significant (p < 0.05).
Bmi-1 silencing made the cells more sensitive to
doxorubicin
After treatment with various concentrations of doxo-
rubicin for 72 h, we found that the Bmi-1si cells showed a
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Figure 4 - Effect of Bmi-1 silencing on cell cycle progression and expression of cyclin D1, p21 of MCF-7 cells. (A) The effect of Bmi-1 silencing on cell
cycleprogressionasshownbyFCM.Cellswereharvested48haftertransfectionandthenstainedwithpropidiumiodide(PI).Bmi-1silencinginducedan
obviousincreaseinthenumberofcellsatG0/G1phaseandreductioninSphase;77.10%oftheMCF-7cellsinBmi-1siwerefoundatG0/G1phase,com-
pared to 63.75% and 64.84% cells in blank control and GFPsi, respectively. There were significant differences between Bmi-1si and controls (p < 0.05).
(B) and (C) Western blot analysis of cyclin D1 and p21 in MCF-7 cells 48 h after transfection. Relative levels of protein are indicated. -actin levels are
shown as loading control. Compared with blank control and GFPsi, a reduction in the expression of cyclin D1 and an increase in the expression of p21
were also noticed (p < 0.05).
Figure 5 - (A) Effect of Bmi-1 silencing on cell apoptosis in MCF-7 cells. Cells were harvested 48 h after transfection and then stained with Annexin/PI
forapoptosisdetection.(a)Blankcontrol,(b)GFPsi,(c)Bmi-1si.ThebasallevelofapoptosisinBmi-1siwas4.94%,whileintheblankcontrolandGFPsi
it was 3.18% and 2.84, respectively. No significant differences in cell apoptosis were noticed among these three groups. (B) Effect of Bmi-1 silencing on
doxorubicin-induced apoptosis. The apoptotic rate was examined in cells after treatment with 1 g/mL doxorubicin for 48 h. (a) Blank control, (b) blank
control treated with 1 g/mL doxorubicin, (c) Bmi-1si, (d) Bmi-1si treated with 1 g/mL doxorubicin. The level of apoptosis in the blank control and
Bmi-1si was 6.70% and 6.72%, respectively. The apoptotic rate in Bmi-1si treated with doxorubicin was 37%, while in the blank control treated with
doxorubicin it was 21%. This difference was significant (p < 0.05).higher IR than the blank control and GFPsi. The IC50 value
of doxorubicin in Bmi-1si was 0.12  0.07 g/mL, com-
pared to 0.86  0.02 g/mL in the blank control and
0.84  0.02 g/mL in GFPsi, respectively (Figure 6). There
were significant differences between the IC50 of Bmi-1si
and that of controls.
Discussion
Previously, BE(2)-C cells infected with Bmi-1
siRNAexpressingretrovirusshoweda70%-80%reduction
in the Bmi-1 protein level (Cui et al., 2006). In the present
study, the same retrovirus vector was used to transiently
transfect MCF-7 cells, resulting in 67% and 70% reduc-
tions of Bmi-1 mRNA and protein levels, respectively.
ThesedataindicatethattheRNAistrategytosilenceBmi-1
is specific and effective.
In this study, we found that the growth of MCF-7 cell
was significantly retarded by Bmi-1 silencing. Because the
Bmi-1-specific growth retardation was mediated by a de-
layed cell cycle progression and/or an increased level of
apoptosis (Meng et al., 2005; Liu et al., 2006a; Yu et al.,
2007), we measured the cell cycle distribution and apop-
tosis ratio by FCM, in order to determine the relation be-
tween inhibition of cell growth and cell cycle arrest or
apoptosis.
According to our results, Bmi-1 silencing both dis-
ruptedcellcycleprogressionandinhibitedG1-Sphasetran-
sition significantly. The increase in the number of cells in
G0/G1 phase and decrease in S phase are consistent with the
previous results observed in K562 (Meng et al., 2005) and
leukemic cells (Lessard and Sauvageau, 2003). Bmi-1 neg-
atively regulates p16
INK4a (Jacobs et al., 1999), which acts
in the P16
INK4a-pRb pathway. P16
INK4a affects pRb by in-
hibiting the cyclin D/cyclin-dependent kinase 4/6 kinase
complex. In the absence of Bmi-1, p16
INK4a may get up-
regulated and prevent binding of cyclin-dependent kinase
4/6 to cyclin D, thus inhibiting kinase activity. This in turn
results in hypophosphorylation of pRb, which ultimately
leads to cell cycle arrest, senescence, or apoptosis, depend-
ing on context (Sherr, 2001). Our study shows that the
marked down-regulation of cyclin D1 might be related to
the inhibition of the G1-S phase transition.
Our results indicate that the expression of p21 protein
was increased. Bmi-1 can negatively regulate ARF, which
probably promotes senescence by regulating the ARF-
p53-p21 pathway (Jacobs et al., 1999; Dimri et al., 2000).
Evidence has shown the key role of p21 in senescence. Ab-
rogation of the p53-p21 pathway by various strategies can
bypass senescence in human and mouse cells, a variety of
stimuli induce senescence in a p53/p21-dependent manner
and enforced expression of p21 in certain cell types can in-
duce a senescence-like phenotype (Dimri, 2005). So, we
conjectured that p21 might be involved in the senescence
induced by Bmi-1 silencing.
Bmi-1 may negatively regulate p19ARF, which se-
questers the p53 inhibitor MDM2 and thereby prevents the
degradation of p53, resulting in p53-mediated apoptosis
(Jacobs et al., 1999). So, loss of Bmi-1 may promote cell
apoptosis (Liu et al., 2006a). However, in agreement with
previousfindingsinhumanI-typeneuroblastomacells(Cui
etal.,2006)andinA549lungcancercells(Yuetal.,2007),
we observed no significant cell apoptosis. This suggests
that Bmi-1 silencing affects cell apoptosis, which may vary
in different cell lines. We therefore conclude that Bmi-1 si-
lencing may induce the inhibition of MCF-7 cell prolifera-
tion through a mechanism that is largely dependent on cell
cycle regulation, but not on apoptosis.
We also studied the role of Bmi-1 on chemother-
apy-induced apoptosis in MCF-7 cells and found that the
down-regulation of Bmi-1 resulted in an increased sensitiv-
ity of these cells to doxorubicin, expressed by apoptosis.
This report is consistent with a previous result observation
in nasopharyngeal carcinoma cells (Qin et al., 2008).
Altogether, our study demonstrates that siRNA tar-
getingofBmi-1ledtotheefficientandspecificinhibitionof
endogenous Bmi-1 mRNA and protein expression of
MCF-7 cells in vitro. Down-regulation of Bmi-1 inhibited
the proliferation and increased the chemosensitivity of
MCF-7 cells, indicating that Bmi-1 can be developed into a
therapeutic option for the treatment of breast cancer. Fur-
ther studies will be directed toward uncovering the mecha-
nism underlying the enhancement of doxorubicin-induced
apoptosis by the silencing of Bmi-1.
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